Moderna Stock: Bull vs. Bear
Moderna (NASDAQ: MRNA) has been a key player in the coronavirus vaccine market from the start. Along with Pfizer and BioNTech, the biotech company has vaccinated most Americans. And Moderna has brought in billions of dollars in revenue and profit.
Moderna shares soared during the earlier stages of the pandemic. From 2020 through last year, they climbed 1,200%. But in recent times, they've lost momentum. This year, the stock has dropped 47%. Are investors too pessimistic about Moderna these days? Here, Motley Food contributors Adria Cimino and Alex Carchidi present the bull and bear cases for this vaccine giant.
Adria Cimino: Moderna is on track to remain a leader in the coronavirus vaccine market for the long term. It delivered a safe and efficacious vaccine when it was most needed. But Moderna didn't stop there. The company began working on candidates that could address the coronavirus market as it evolves.
Source Fool.com
